Table 1.

Clinical charts of 12 patients with chronic pancreatitis and acute oxalate nephropathy

Patients (n = 12)
    age at onset (year)67 (41 to 90)
    gender (men/women)9/3
Kidney involvement
    renal status before AON
        serum creatinine (μmol/L)96 (70 to 179)
        eGFR (ml/min per 1.73 m2, MDRD)57 (36 to 89)
        CKD stage2 (n = 5)/3 (n = 7)
    renal status at presentation
        serum creatinine (μmol/L)587 (294 to 849)
        serum calcium (mmol/L)1.69 (1.09 to 2.62)
        serum PTH (pg/ml)262 (63 to 750)
        urine protein (g/d)0.34 (0.05 to 1.01)
        leucocyturia (n)10
        hematuria (n)3
        urine oxalate (mg/day; n ≤ 45)80 (52 to 92)
        oligoanuria3
Pancreas involvement
    prior diagnosis of chronic pancreatitis8
        duration (years)10 (2 to 17)
    diabetes mellitus9
        duration (years)(6 to 16)
        treatment (OAD/insulin)3/6
    exocrine pancreatic insufficiency7
        known before AON
            pancreatic enzyme supplementation6
        unknown before AON5
            low fecal elastase at recognition of AON5
    pancreas imaging
        gland atrophy or heterogeneity9
        calcifications10
        Wirsung bud dilatation2
        pseudocysts1
Potential triggers of AON
    acute diarrhea5
    massive ascorbic acid intake1
    diuretics/RAS blockers5/8
    recent antibiotherapy4
Renal outcome at last follow-up
    duration (months)7 (2 to 60)
    serum creatinine (μmol/L) in patients free of RRT212 (98 to 410)
    eGFR (ml/min per 1.73 m2)17 (0 to 55)
    CKD stage 2/3/4 (n)1/4/4
    RRT3
  • Median values are presented with their ranges in parentheses. All other values indicate the number of patients, unless specified otherwise. AON, acute oxalate nephritis; CKD, chronic kidney disease; eGFR, estimated GFR; OAD, oral antidiabetic drug; PTH, parathormone level; RAS, renin-angiotensin system; RRT, renal replacement therapy.